In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the Transition to Biosimilars.
Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the “Régie de l’Assurance Maladie du Québec” (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ will reimburse Biosimilar insulins of its original insulins.
